GenFleet and Innovent Starts First-in-human Phase I/II Trial of KRAS G12C Inhibitor

/PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, and Innovent...

Related Keywords

Rhui Zhou ,Guangdong ,China ,Guangzhou ,Yu Wang ,Henan ,Taiwan ,Hong Kong ,Jilin ,Macau ,Chinese ,Innovent Biologics ,Adimab Incyte ,Eli Lilly ,Yilong Wu ,Clinical Development Of Innovent ,Md Anderson Cancer Center ,Guangdong Lung Cancer Institute ,Genfleet Therapeutics ,Guangdong Provincial People ,Guangdong Lung Cancer ,Chief Medical Officer ,Senior Vice President ,Clinical Development ,Fleet Therapeutics ,Main Board ,Stock Exchange ,Hong Kong Limited ,Biologics License Application ,Cancer Center ,Biotechnology ,Health Care Amp Hospitals ,Clinical Trials Amp Medical Discoveries ,